Alternately, SERT inhibitors might worsen Parkinsonism via a 5-HT-mediated activation of presynaptic 5-HT1A receptors [127], which would result in less dopamine being released from raphe-striatal terminals. This evidence concerns the gene HTR1A and Parkinson disease.